Bristol Myers Squibb and Microsoft have formalised a strategic collaboration to harness artificial intelligence for transforming lung cancer detection and management. The multi-year agreement, revealed on January 16, 2026, brings together BMS’s extensive oncology clinical data and scientific insight with Microsoft’s Azure cloud platform, advanced AI research teams, and expertise in building secure, scalable healthcare solutions.

Lung cancer remains the leading cause of cancer death globally, with late-stage diagnosis contributing significantly to poor survival rates. While low-dose CT screening has proven effective in high-risk populations, challenges persist: high false-positive rates lead to unnecessary invasive procedures, radiologist workload is increasing, and access to expert interpretation varies widely. The BMS–Microsoft partnership aims to address these pain points by developing next-generation AI models capable of detecting subtle nodules, characterising malignancy risk, predicting progression, and prioritising cases for human review.

The collaboration will leverage multimodal data including CT imaging, pathology reports, genomic profiles, and longitudinal clinical outcomes to train robust, generalisable AI algorithms. Microsoft’s Azure AI Health tools and responsible AI principles will ensure transparency, fairness across diverse populations, strong data governance, and compliance with global regulatory standards including HIPAA and GDPR.

Early focus areas include improving the positive predictive value of lung nodule detection, reducing time-to-diagnosis in screening programmes, and supporting more precise treatment selection in early-stage disease. The models are being designed to integrate seamlessly into existing radiology PACS systems and clinical workflows, enabling radiologists to review AI-assisted findings without disrupting established processes.

Robert Plenge, MD, PhD, Executive Vice President and Chief Scientific Officer at BMS, said: “Lung cancer is a devastating disease where earlier, more accurate detection can meaningfully change patient trajectories. By combining our deep oncology expertise and real-world data with Microsoft’s AI and cloud capabilities, we are building tools that have the potential to save lives through earlier intervention and more personalised care.”

Pavan Yalamanchili, Corporate Vice President, Microsoft Health & Life Sciences, added: “This collaboration reflects our shared commitment to responsible AI that augments clinical decision-making rather than replacing it. We are excited to work with BMS to create scalable, trustworthy solutions that can make a real difference in lung cancer outcomes worldwide.”

The partnership builds on Microsoft’s growing portfolio of healthcare AI collaborations and BMS’s ongoing investment in data-driven precision oncology. Initial results from model development are expected to be shared in scientific publications and at major oncology conferences throughout 2026, with prospective clinical validation studies planned in multiple geographies.

This alliance underscores the accelerating convergence of large-scale oncology data, cloud-scale computing, and advanced AI positioning lung cancer care as a proving ground for next-generation precision diagnostics that could eventually influence screening, diagnosis, and treatment pathways globally.